Skip to Content

Dr Reddy's Laboratories Ltd ADR RDY

Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Dr. Reddy's Posts Solid Results After Strong Season of Product Launches

Damien Conover, CFA Sector Director

Analyst Note

| Damien Conover, CFA |

Dr. Reddy’s posted solid second-quarter results. A confluence of factors led to strong top line growth, but we place this in perspective against the high costs of maintaining market share in this industry long-term. We maintain our fair value estimate of $49 per share and our no-moat rating.

Read Full Analysis

Company Profile

Business Description

With headquarters in India, Dr. Reddy's Laboratories develops and manufactures generic pharmaceuticals. The firm operates in three divisions: global generics, pharmaceutical services and active ingredients, and proprietary products and other, which make up most of the company's revenue. Most of the company’s sales are based in the United States.

Contact
8-2-337, Road No. 3, Banjara Hills
Hyderabad, TG, 500 034, India
T +91 4049002900
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Sep 30, 2021
Fiscal Year End Mar 31, 2022
Stock Type
Employees 22,739